Protalix BioTherapeutics
(NYSEMKT) PLX
Protalix BioTherapeutics Financials at a Glance
Market Cap
$170.01M
Revenue (TTM)
$76.38M
Net Income (TTM)
$15.33M
EPS (TTM)
$0.18
P/E Ratio
11.51
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Price
$2.11
Volume
487,911
Open
$2.10
Price
$2.11
Volume
487,911
Open
$2.10
Previous Close
$2.11
Daily Range
$2.07 - $2.14
52-Week Range
$1.32 - $3.19
Dividend
$0.00
Beta (Volatility)
0.70 (Low)
Price
$2.11
Volume
487,911
Open
$2.10
Previous Close
$2.11
Daily Range
$2.07 - $2.14
52-Week Range
$1.32 - $3.19
PLX News
Is This Orphan Drugmaker in Trouble?
5 of Last Week's Biggest Losers
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Protalix BioTherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
226
CEO
Dror Bashan, MBA
Website
www.protalix.comHeadquarters
Hackensack, NJ 07601, US
PLX Financials
Key Financial Metrics (TTM)
Gross Margin
70%
Operating Margin
26%
Net Income Margin
20%
Return on Equity
27%
Return on Capital
26%
Return on Assets
15%
Earnings Yield
8.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$170.01M
Shares Outstanding
80.57M
Volume
487.91K
Avg. Volume
888.88K
Financials (TTM)
Gross Profit
$25.24M
Operating Income
-$5.50M
EBITDA
-$4.04M
Operating Cash Flow
-$11.99M
Capital Expenditure
-$1.64M
Free Cash Flow
-$13.63M
Cash & ST Invst.
$30.27M
Total Debt
$8.32M
Protalix BioTherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$33.75M
+233.7%
Gross Profit
$29.62M
+1432.5%
Gross Margin
87.77%
N/A
Market Cap
$170.01M
N/A
Market Cap/Employee
$798.15K
N/A
Employees
213
N/A
Net Income
$18.32M
+606.1%
EBITDA
$21.55M
+667.3%
Quarterly Fundamentals
Net Cash
$43.31M
+46.8%
Accounts Receivable
$2.94M
-37.1%
Inventory
$30.47M
+56.2%
Long Term Debt
$7.05M
+84.9%
Short Term Debt
$1.43M
+0.6%
Return on Assets
14.98%
N/A
Return on Invested Capital
26.41%
N/A
Free Cash Flow
$21.26M
+496.4%
Operating Cash Flow
$22.03M
+535.4%